ストックスクリーナーアプリを入手
0.9899
0.01%
-0.000100
プレマーケット:
.97
-0.0199
-2.01%
前日終値:
$0.99
開ける：
$0.99
24時間の取引高:
151.61K
Relative Volume:
0.13
時価総額：
$1.57M
収益：
$4.70M
当期純損益:
$-4.99M
株価収益率:
-0.1542
EPS:
-6.42
ネットキャッシュフロー:
$-5.29M
1週間 パフォーマンス:
-13.92%
1か月 パフォーマンス:
+18.58%
6か月 パフォーマンス:
-40.72%
1年 パフォーマンス:
-59.60%
1日の値動き範囲:
$0.89
$1.01
1週間の範囲:
$0.89
$1.21
52週間の値動き範囲:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
名前
Salarius Pharmaceuticals Inc
セクター
電話
346-772-0346
住所
2450 HOLCOMBE BLVD, HOUSTON
SLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.9899 | 1.57M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-04-27 | 開始されました | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc (SLRX) 最新ニュース
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga
Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks
Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia
Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Salarius: Q1 Earnings Snapshot - New Haven Register
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 2.1% – Here’s Why - Defense World
Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Closing Figures Unveiled: Salarius Pharmaceuticals Inc (SLRX) Drop -26.34, Closes at 0.60 - DWinneX
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches By Investing.com - Investing.com Canada
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Robert S. Langer To Scientific Advisory Board - citybiz
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - The Manila Times
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com India
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech
SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire
Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World
SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com
SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering - Investing.com
Salarius Pharmaceuticals Inc (SLRX) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):